GlassScriptPhysician profile
Zeenat Ali
NPI 1821224692
$7,590.08
in general payments reported to CMS, 2019-2025
34 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $75.22 · 2021: $250 · 2022: $1,432 · 2023: $1,577 · 2024: $1,494 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Consulting Fee: $320 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.31 |
| Consulting Fee | $320.00 |
| Education | $313.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,008.09 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $1,187.93 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,030.79 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $890.64 | 2019-2025 | Enbrel, Otezla, Enbrel |
| Glaxosmithkline, LLC. | $428.61 | 2022-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $348.55 | 2019-2025 | Orencia |
| Lilly USA, LLC | $214.00 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $182.57 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $168.19 | 2019 | |
| Janssen Scientific Affairs, LLC | $130.93 | 2022 | |
| Organon LLC | $122.19 | 2024-2025 | Hadlima, Renflexis |
| Pfizer INC. | $120.68 | 2019-2025 | |
| Horizon Therapeutics Plc | $84.82 | 2019-2023 | |
| Almatica Pharma LLC | $83.06 | 2024 | Teriparatide |
| Sandoz INC. | $62.66 | 2023-2024 | Hyrimoz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $60.88 | 2024-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $59.99 | 2025 | Acthar |
| Abbott Laboratories | $45.09 | 2021 | |
| Ani Pharmaceuticals, INC. | $41.58 | 2022 | |
| Sobi, INC | $40.53 | 2019 | |
| Aurinia Pharma U.S., INC. | $40.24 | 2024-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $24.57 | 2023 | |
| Hospira, INC. | $24.54 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2022 | |
| Genzyme Corporation | $21.48 | 2025 | |
| Merck Sharp & Dohme LLC | $21.05 | 2022 | |
| Tonix Medicines, INC. | $20.04 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $19.98 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $19.61 | 2022 | |
| Radius Health, INC. | $15.31 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $12.98 | 2019 | |
| Hikma Pharmaceuticals USA | $12.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeenat Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.